This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Icon PLC (ICLR) Up 2.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Icon PLC (ICLR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Elevance Health (ELV) Up 7.3% Since Last Earnings Report?
by Zacks Equity Research
Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pediatrix (MD) Q2 Earnings Top on Stable Volumes, Shares Up 7.4%
by Zacks Equity Research
Pediatrix's (MD) second-quarter earnings benefit from stable patient volumes. Rising expenses act as a partial offset.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
Select Medical's (SEM) Stock Down 16.9% Despite Q2 Earnings Beat
by Zacks Equity Research
Select Medical (SEM) expects its adjusted EBITDA between $845 million and $885 million for 2024, the mid-point of which implies a 7.1% rise from the 2023 reported figure of $807.4 million.
Teladoc Health (TDOC) Shares Down 8.9% Despite Q2 Earnings Beat
by Zacks Equity Research
Teladoc Health (TDOC) expects revenue growth in the Integrated Care segment to be within low to mid-single-digit growth in 2024, on a year-over-year basis.
Cigna (CI) Q2 Earnings Top on Specialty Business Strength
by Zacks Equity Research
Cigna's (CI) Q2 results reflect new client wins in the Evernorth Health Services unit, partly offset by elevated pharmacy costs. It continues to expect adjusted EPS of at least $28.40 for 2024.
Ensign Group (ENSG) Q2 Earnings Beat on Occupancy, Stock Up 7.2%
by Zacks Equity Research
Ensign Group's (ENSG) second-quarter results benefit from improved occupancy and skilled services revenue. Higher expenses partially offset the results.
UnitedHealth (UNH) Q2 Success: A Turnaround Worth Investing in?
by Kaibalya Pravo Dey
UnitedHealth (UNH) is navigating its challenges effectively, maintaining a positive outlook for the future while demonstrating a strong commitment to its clients and shareholders.
Centene (CNC) Q2 Earnings Miss on Declining Medicaid Membership
by Zacks Equity Research
Centene's (CNC) second-quarter earnings suffer from rising operating expenses and a decline in Medicaid membership levels. Improved Marketplace membership growth partially offset the negatives.
Community Health (CYH) Q2 Earnings Miss on Lower Patient Days
by Zacks Equity Research
Community Health's (CYH) second-quarter earnings suffer a setback from lower admissions and patient days. Improved occupancy levels partially offset the negatives.
Universal Health (UHS) Q2 Earnings Beat on Acute Care Strength
by Zacks Equity Research
Universal Health's (UHS) second-quarter results benefit from the rising number of patients in the Acute Care Unit. Declining admissions in the Behavioral Health segment partially offset the positives.
Tenet (THC) Q2 Earnings Beat on Patient Volumes, '24 EPS View Up
by Zacks Equity Research
Tenet Healthcare's (THC) Q2 results reflect net revenue per case growth, higher pricing yield and a decline in overall expenses. It expects 2024 adjusted EPS within $10.41-$11.12, up from the previous guidance of $8.37-$9.41.
The Zacks Analyst Blog Highlights S&P Global, Honeywell International, Elevance Health and Sypris Solutions
by Zacks Equity Research
S&P Global, Honeywell International, Elevance Health and Sypris Solutions are part of the Zacks Top Analyst Blog.
Q2 Earnings Season Scorecard and Today's Analyst Reports for Honeywell, Elevance Health & Others
by Sheraz Mian
Today's Research Daily features a real-time earnings season scorecard and updated research reports S&P Global (SPGI), Honeywell (HON) and Elevance Health(ELV), as well a micro-cap stock Sypris Solutions, Inc. (SYPR).
Boston Scientific (BSX) Banks on Global Expansion, Innovation
by Zacks Equity Research
In EMEA, Boston Scientific (BSX) is successfully expanding its base, banking on its diverse portfolio, new launches and commercial execution with healthy underlying market demand.
Glaukos (GKOS) Gains 51.9% YTD: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
GE HealthCare (GEHC) New Deal to Aid Its Ultrasound Portfolio
by Zacks Equity Research
GE HealthCare (GEHC) announces that it has entered into an agreement to acquire Intelligent Ultrasound's AI software business to strengthen its ultrasound portfolio.
Hyperfine's (HYPR) Swoop System Gets New FDA-Cleared Software
by Zacks Equity Research
Hyperfine (HYPR) announces the receipt of FDA clearance for its ninth-generation AI-powered Swoop system software.
Elevance Health's (ELV) Q2 Earnings Beat on Lower Benefit Expense
by Zacks Equity Research
Elevance Health's (ELV) Q2 results gain on strong product revenue growth in the Carelon business and a reduced overall expense level. Adjusted earnings are reiterated to be at a minimum of $37.20 per share in 2024.
Smith & Nephew's (SNN) CATALYSTEM System Gets FDA Clearance
by Zacks Equity Research
Smith & Nephew (SNN) announces the receipt of FDA clearance for its new CATALYSTEM Primary Hip System, which is intended to address the demands of primary hip surgery.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Elevance Health (ELV) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Elevance Health (ELV) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Elevance Health (ELV) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Elevance Health (ELV) delivered earnings and revenue surprises of 1.30% and 0.54%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Catalent (CTLT) Expands Its Facility Capabilities in Germany
by Zacks Equity Research
Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Development & Supply network.